Article
Paclitaxel Resistance in Ovarian Cancers Relies on a PGAM1 Mediated Glycolytic Metabolism
2020-11-09
Abstract excerpt
<title>Abstract</title> <p>Background: Paclitaxel, as an anti-microtubule drug, has been recommended to be the first-line chemotherapy agent for ovarian cancer for about two decades. However, most patients with advanced stage relapse within two years and ultimately die of relapsed cancer displaying increased chemoresistance. The mechanisms underlying paclitaxel resistance remain ncompletely understood. <h4>Method...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1adcdb2a-4728-5487-913a-5eba8e5fc78e
- DOI
- 10.21203/rs.3.rs-103118/v1
